VRTX
Vertex Pharmaceuticals Inc / Ma
A global biotech developing transformative medicines for serious diseases, Vertex Pharmaceuticals is best known for its cystic fibrosis franchise — KALYDECO, ORKAMBI, SYMDEKO, TRIKAFTA, and ALYFTREK — which treats most people with CF in key Western markets. The company also makes CASGEVY, a CRISPR gene-editing therapy for sickle cell disease and beta thalassemia, and JOURNAVX, a non-opioid pain signal inhibitor for acute pain. Its pipeline targets kidney disease, chronic pain, and type 1 diabetes.
CUSIP: 92532F100ISIN: US92532F1003HealthcareUS4 holders
Total Value
$39.61M
Total Shares
79.7K
Net Share Change
-3.6K
Activity
4 selling
Investor
Value
Shares
Weight
Change
